November 10, 2023, Cell Therapy Startup CARGO TherapeuticsIPO on NASDAQ, issuing 18.75 million shares at $15 per share to raise $281 million.Currently, the market value of CARGO is $1.02 billion.

Cargo Therapeutics was founded in 2021 by cell therapy scholars from Stanford University.Dedicated to developing First in Class and Best in Class CD22 CAR-T cell therapies, as well as next-generation CAR-T cell therapies.。Cargo Therapeutics uses itsProprietary Cell Engineering Platform Technology，Develop a series of projects, which include various transgenic therapeutic "vectors," aimed at enhancing the presence and persistence of CAR T cells inTransport in tumor lesions, while helping to prevent tumor drug resistance and T-cell exhaustion.From its establishment to IPO, Cargo Therapeutics only took a short span of 2 years.During this period, it underwent two rounds of financing:January 2022,CargoSecured $11 million in seed funding and $32 million in bridge financing;March 2023,CargoCompleted a $200 million oversubscribed Series A financing round.

R&D Pipeline

Cargo Core PipelineCRG-022, is a potential "First/Best in class" autologous CD22 CAR-T cell therapy aimed at treating patients with relapsed or refractory large B-cell lymphoma, currently in the phase 2 trial stage.

On November 3, 2023, LEXEO Therapeutics, a biotechnology company focused on gene drug researchIPO on Nasdaq, at $11/ThighPriceIssue9090910Stock,Raised $100 million.Currently, LEXEO Therapeutics is valued at $386 million.

LexeoFounded in 2018, with its headquarters in New York State, USA, it is a company dedicated to developing gene therapies for cardiovascular diseases and Alzheimer's disease.Once selectedFierce Biotech’s 2022 Fierce 15BioSpace Selected as a 2022 Next-Gen Bio Newcomer Company.

In 2021,LexeoAcquisition of Stelios Therapeutics Brings Three Cardiomyopathy Gene Therapy Programs. Currently,LEXEO Therapeutics has 7 pipelines in the fields of heart disease and neurological disorders.

R&D Pipeline

Lexeo Gene Therapy for Alzheimer's DiseaseLX1001Aiming to deliver the APOE2 gene for treating Alzheimer's disease patients homozygous for the APOE4 gene. It is currently in Phase 1/2 clinical trials, covering approximately 15 Alzheimer's disease patients aged over 50.

Lexeo The most advanced candidate drugLX2006, is an AAV gene therapy that was approved for clinical trials in humans in February 2023, becoming the first gene therapy for Friedreich's ataxia to be approved for clinical use. The drug alsoGranted by the FDA"Rare Pediatric Disease" Designation and "Orphan Drug" Designation,Currently inPhase I/II Clinical TrialsParagraph,More data expected to be released in mid-2024.

AAV Gene TherapyLX2020，For the treatment of arrhythmogenic cardiomyopathy caused by PKP2 gene mutations,Received FDA IND Approval in August 2023; December 2023Granted FDA Fast Track Designation and Orphan Drug Status;The Phase 1/2 clinical trial is expected to begin in the first half of 2024, with interim data from Cohort 1 planned for release in the second half of 2024.

TIL TherapyTurnstone Biologics, Inc. went public on NASDAQ through an IPO at $12 per share on July 21, 2023.PriceIssue6,666,667 sharesStock, raising 80 million US dollars.Currently, TurnstoneThe market value of Biologics is 69.07 million US dollars.

This IPO is being carried out amid a cash crunch for the company, and without a successful IPO,TurnstoneThe operation will be a cause for concern.

Turnstone Biologics, founded in 2015, initially focused on developing oncolytic virus therapies for malignant tumors, but later shifted its focus to TIL therapy.Turnstone’s proprietary technology platform combines the means to discover tumor-associated T cells in TIL with advanced cell screening and culture techniques, enabling the rapid enrichment of tumor-destroying T cells, preserving the diversity of T-cell-targeted antigens, while reducing the manufacturing time for TIL therapy.

R&D Pipeline

TurnstoneTheTILTherapyTIDAL-01Two Phase 1b clinical trials are being conducted in patients with melanoma, breast cancer, and colorectal cancer.

March 27th, Beijing |Click on the image to register now ↓↓